Bergen, Norway, May 28, 2024, - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announced today that it has entered into a clinical
trial agreement with the Mays Cancer Center at The University of Texas Health
Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan
Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical
company.

The parties will collaborate to study BerGenBio's selective AXL inhibitor,
bemcentinib, in combination with Sobi's pacritinib in patients with advanced
lung adenocarcinoma. The clinical study is externally funded and is
complementary to BerGenBio's ongoing Ph1b/2a clinical study in first-line Non
-Small Cell Lung Cancer patients with mutations in the STK11 gene.

Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL
receptor tyrosine kinase, a promising therapeutic target for serious diseases.
Pacritinib (marketed as VONJO®) is a JAK2 inhibitor indicated for treatment of
myelofibrosis, a bone marrow disorder, and works by blocking certain growth
factors and cytokines.

The clinical study will advance the ground-breaking work of Josephine A.
Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Assistant
Professor in the Division of Hematology and Oncology at UT Health San Antonio.
Dr. Taverna's prior research has demonstrated that AXL and JAK-STAT3 work
together to transmit signals that promote tumor growth and metastasis in
advanced lung cancer. The study will be performed in collaboration with Sobi®
and will be led by Dr. Taverna as the principal investigator and is funded by a
grant received from the National Cancer Institute (NCI) of the National
Institutes of Health (NIH).

Martin Olin, Chief Executive Officer of BerGenBio stated, "We are excited to
work with two stellar partners to bring this intriguing area of research to
patients. This study will further extend our knowledge of the role of selective
AXL inhibition with bemcentinib in lung cancer, our area of highest strategic
focus."

Dr. Taverna commented, "Our data suggests that targeting the AXL-STAT3 pathway
with bemcentinib and pacritinib can prevent tumor cells from recruiting tumor
-associated macrophages and other aggressive host cells into the tumor
microenvironment, disrupting tumor growth and metastatic spread. Understanding
this discovery could shed light on novel therapeutic strategies for lung
cancer."

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com



Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visitwww.bergenbio.com

About Mays Cancer Center at UT Health San Antonio

The Mays Cancer Center at UT Health San Antonio (https://cancer.uthscsa.edu/) is
one of only four National Cancer Institute-designated Cancer Centers in Texas.
The Mays Cancer Center provides leading-edge cancer care, propels innovative
cancer research and educates the next generation of leaders to end cancer in
South Texas. To learn more, visit https://cancer.uthscsa.edu.

Stay connected with the Mays Cancer Center
onFacebook (https://www.facebook.com/UTHealthsaMDAnderson),Twitter (https://twit
t
er.com/UTHealthSAMDA),LinkedIn (https://www.linkedin.com/company/uthealthsa),Ins
t
agram (https://www.instagram.com/uthealthsamdanderson/)andYouTube (https://www.y
o
utube.com/@uthealthsamdanderson).



About The University of Texas Health Science Center at San Antonio

The University of Texas Health Science Center at San
Antonio (https://www.uthscsa.edu/) (UT Health San Antonio) is one of the
country's leading health science universities and is designated as a Hispanic
-Serving Institution by the U.S. Department of Education. With missions of
teaching, research, patient care and community engagement, its schools of
medicine, nursing, dentistry, health professions, graduate biomedical sciences
and public health have graduated more than 42,550 alumni who are leading change,
advancing their fields and renewing hope for patients and their families
throughout South Texas and the world. To learn about the many ways "We make
lives better®," visit
UTHealthSA.org (https://uthscsa.edu/?utm_source=uthealthsaorg&utm_medium=pagered
i
rect&utm_campaign=uthealthsa).

Stay connected with The University of Texas Health Science Center at San Antonio
onFacebook (https://www.facebook.com/UTHealthSA),Twitter (https://twitter.com/ut
h
ealthsa),LinkedIn (https://www.linkedin.com/company/uthealthsa),Instagram (https
:
//www.instagram.com/uthealthsa/)andYouTube (https://www.youtube.com/uthscsa/).

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.



This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.